Hang Lung Properties Limited (HLPPY)
| Market Cap | 5.05B |
| Revenue (ttm) | 1.29B |
| Net Income (ttm) | 255.29M |
| Shares Out | n/a |
| EPS (ttm) | 0.05 |
| PE Ratio | 19.79 |
| Forward PE | 12.64 |
| Dividend | 0.30 (5.87%) |
| Ex-Dividend Date | May 8, 2025 |
| Volume | 449 |
| Average Volume | 6,345 |
| Open | 5.22 |
| Previous Close | 5.16 |
| Day's Range | 5.00 - 5.22 |
| 52-Week Range | 3.30 - 5.49 |
| Beta | 0.65 |
| RSI | 69.27 |
| Earnings Date | Jul 29, 2025 |
About CTI BioPharma
Hang Lung Properties Limited, an investment holding company, engages in the property investment, development, and management activities in Hong Kong and Mainland China. It operates through Property Leasing, Property Sales, and Hotel segments. The company is involved in the development, lease, and sale of properties. Its investment properties portfolio includes shopping malls, office and residential premises, retail, serviced apartment, hotel, and car parking properties, as well as industrial premises. The company also engages in the apartment o... [Read more]
Financial Performance
In 2024, Hang Lung Properties's revenue was 11.27 billion, an increase of 8.85% compared to the previous year's 10.35 billion. Earnings were 2.15 billion, a decrease of -45.77%.
Financial StatementsNews
Hang Lung earnings drop 14% as developer flags risks from tariff war, rates
Hong Kong developer Hang Lung Properties expects the city’s retail sector to remain sluggish this year amid a prolonged industry slump, while an unresolved tariff war with the US keeps businesses and ...
Hang Lung Properties' Adriel Chan: still conservative on residential property in HK and mainland China
Adriel Chan, Chair of Hang Lung Properties talks about property market outlook and the company's continued efforts to deleverage.
Hang Lung Properties profit slumps 46% on lower leasing profits, higher finance costs
Company says it faces headwinds in China and Hong Kong.